The BalancedInvestor Club

QNTM Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-7.730.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$31.2MMicro cap

Valuation

Forward P/E
—
PEG ratio
—
P/B
56.65
P/S (TTM)
91.86
EV/EBITDA
-1.57

Profitability & growth

ROE (TTM)
-2057.0%
Operating margin
0.0%
Revenue growth YoY
0.0%
Dividend yield
—
Beta
0.36
Last earnings
May 7, 2026 · Estimate $-0.68 · Reported $-4.17
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 43 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on developing transformative therapies targeting oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products and a strong emphasis on research and development, Quantum leverages advanced technologies to address unmet medical needs. The company’s strategic collaborations and experienced leadership contribute to its competitive edge, positioning it well for growth in the dynamic biopharmaceutical landscape. As the market for novel therapeutics expands, QNTM presents an appealing investment…

Classification

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
1 ADELAIDE STREET EAST, TORONTO, ON
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$31.2M
Shares outstanding$6.4M
52W high$38.25
52W low$2.07

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer